Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
4.490
-0.110 (-2.39%)
May 13, 2025, 4:00 PM - Market closed
Amylyx Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Cash & Equivalents | 59.76 | 77.39 | 170.2 | 62.53 | 50.19 | 12.88 | Upgrade
|
| Short-Term Investments | 144.3 | 99.11 | 201.16 | 284.42 | 45.93 | - | Upgrade
|
| Cash & Short-Term Investments | 204.07 | 176.5 | 371.36 | 346.95 | 96.12 | 12.88 | Upgrade
|
| Cash Growth | -45.33% | -52.47% | 7.04% | 260.96% | 646.43% | 320.13% | Upgrade
|
| Accounts Receivable | 0.3 | 0.45 | 40.05 | 15.31 | - | - | Upgrade
|
| Other Receivables | - | 0.1 | 0.5 | 0.5 | - | - | Upgrade
|
| Receivables | 0.3 | 0.55 | 40.55 | 15.81 | - | - | Upgrade
|
| Inventory | - | - | 38.32 | 9.77 | - | - | Upgrade
|
| Prepaid Expenses | 11.78 | 12.38 | 14.43 | 9.61 | 5.39 | 0.76 | Upgrade
|
| Other Current Assets | - | - | - | - | 3.44 | - | Upgrade
|
| Total Current Assets | 216.14 | 189.43 | 464.67 | 382.13 | 104.95 | 13.64 | Upgrade
|
| Property, Plant & Equipment | 2.07 | 2.73 | 6.41 | 8.14 | 0.47 | 0.15 | Upgrade
|
| Other Long-Term Assets | 1.46 | 1.47 | 46.38 | 1.19 | 0.19 | 0.31 | Upgrade
|
| Total Assets | 219.68 | 193.63 | 517.45 | 391.45 | 105.61 | 14.1 | Upgrade
|
| Accounts Payable | 4.81 | 2.94 | 22.06 | 6.26 | 4.37 | 3.61 | Upgrade
|
| Accrued Expenses | 12.07 | 23.95 | 57.72 | 38.31 | 13.02 | 3.71 | Upgrade
|
| Current Portion of Leases | 1.06 | 1.52 | 2.26 | 2.04 | - | - | Upgrade
|
| Total Current Liabilities | 17.93 | 28.41 | 82.04 | 46.61 | 17.4 | 7.33 | Upgrade
|
| Long-Term Debt | - | - | - | - | - | 1.43 | Upgrade
|
| Long-Term Leases | 0.33 | 0.46 | 1.98 | 4.24 | - | - | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | 0.04 | 0.02 | Upgrade
|
| Total Liabilities | 18.26 | 28.87 | 84.02 | 50.85 | 17.43 | 8.77 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 844.01 | 771.54 | 738.18 | 694.91 | 4.67 | 1.19 | Upgrade
|
| Retained Earnings | -642.6 | -606.69 | -304.95 | -354.22 | -155.85 | -67.91 | Upgrade
|
| Comprehensive Income & Other | - | -0.09 | 0.2 | -0.09 | 0.01 | - | Upgrade
|
| Total Common Equity | 201.42 | 164.77 | 433.43 | 340.61 | -151.17 | -66.73 | Upgrade
|
| Shareholders' Equity | 201.42 | 164.77 | 433.43 | 340.61 | 88.18 | 5.34 | Upgrade
|
| Total Liabilities & Equity | 219.68 | 193.63 | 517.45 | 391.45 | 105.61 | 14.1 | Upgrade
|
| Total Debt | 1.38 | 1.98 | 4.24 | 6.28 | - | 1.43 | Upgrade
|
| Net Cash (Debt) | 202.69 | 174.52 | 367.13 | 340.67 | 96.12 | 11.45 | Upgrade
|
| Net Cash Growth | -45.16% | -52.46% | 7.77% | 254.43% | 739.31% | - | Upgrade
|
| Net Cash Per Share | 2.79 | 2.56 | 5.25 | 5.82 | 14.59 | 1.88 | Upgrade
|
| Filing Date Shares Outstanding | 89.14 | 88.6 | 67.78 | 66.72 | 57.86 | 6.43 | Upgrade
|
| Total Common Shares Outstanding | 89.08 | 68.63 | 66.51 | 66.51 | 7.02 | 5.99 | Upgrade
|
| Working Capital | 198.21 | 161.03 | 382.62 | 335.52 | 87.56 | 6.31 | Upgrade
|
| Book Value Per Share | 2.26 | 2.40 | 6.52 | 5.12 | -21.53 | -11.13 | Upgrade
|
| Tangible Book Value | 201.42 | 164.77 | 433.43 | 340.61 | -151.17 | -66.73 | Upgrade
|
| Tangible Book Value Per Share | 2.26 | 2.40 | 6.52 | 5.12 | -21.53 | -11.13 | Upgrade
|
| Machinery | - | 1.92 | 3.55 | 2.17 | 0.34 | 0.05 | Upgrade
|
| Construction In Progress | - | 0.22 | 0.59 | 0.8 | 0.14 | 0.06 | Upgrade
|
| Leasehold Improvements | - | 0.18 | 0.18 | 0.18 | 0.05 | 0.04 | Upgrade
|
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.